Dosage & Administration Efficacy safety testing Drug label Samples Prior authorization Financial assistance

Sutent

(sunitinib)

sunitinib 12.5 MG Oral Capsule [Sutent]sunitinib 25 MG Oral Capsule [Sutent]

View 2 more

BLACK BOX WARNING

Dosage & administration

GIST and Advanced RCC:

* The recommended dosage is 50 mg orally once daily for the first 4 weeks of each 6-week cycle (Schedule 4/2).

Adjuvant Treatment of RCC:

* The recommended dosage is 50 mg orally once daily for the first 4 weeks of a 6-week cycle (Schedule 4/2) for a maximum of 9 cycles.

pNET:

* The recommended dosage is 37.5 mg orally once daily.

Sutent clinical details

Dosing & Administration

Dose Modifications: CYP3A Coadministration

Dose Modifications: Adverse Reactions

Important Safety Information

Efficacy: Adjuvant Treatment of RCC - Primary Endpoint

Safety Profile: Adjuvant Treatment of RCC

Efficacy: Advanced RCC - Primary Endpoint

Efficacy: Advanced RCC - Secondary Endpoints

Safety Profile: Advanced RCC

Efficacy: Advanced Pancreatic Neuroendocrine Tumors (pNET) - Primary Endpoint

Efficacy: Advanced Pancreatic Neuroendocrine Tumors (pNET) - Secondary Endpoints

Safety Profile: Advanced Pancreatic Neuroendocrine Tumors (pNET)

Efficacy: Imatinib-resistant or Intolerant GIST - Primary Endpoint

Efficacy: Imatinib-resistant or Intolerant GIST - Secondary Endpoints

Safety Profile: Imatinib-resistant or Intolerant GIST

drug label

Sutent prescribing information

Have more Sutent questions?

Submit MSL Request

Learn More

Need to report a Sutent issue?

ONLINE FORMReport adverse event

Learn More

samples

Request Sutent samples

Online Sample Form

Learn More

prior authorization

Sutent Prior authorization resources

Complete Letter of Medical Necessity

NOT PROVIDED BY BRANDCoverage Authorization Request

Coverage Authorization Appeals

Formulary Exception Letter

Learn More

Benefits investigation

Pfizer Oncology Together Form

Pfizer Oncology Together Form - Spanish

Learn More

Reimbursement help (FRM)

Receive Assistance from an FRM Regarding Reimbursement Information

Learn More

financial assistance

Sutent Financial assistance options

Co-pay savings program

commercial only

Enroll in Patient Savings Program

HCP Office : Attest & Print Co-Pay Card

Learn More

Overview

Reduce patient OOP costs for drug (and occasionally for drug administration/infusion costs or drug-related test costs)

Patient benefit

A portion (or all) of patient OOP (deductible, copay), typically up to monthly and/or annual max

Patient eligibility

Patient must enroll or activate (may permit HCPs to enroll on patient’s behalf for HCP-administered drugs)
Generally, must have commercial insurance (rarely, may permit uninsured patients to use)
May never be used with government insurance

How to sign up

Cards may be downloadable digital cards or hard copies
Some pharmacos offer debit cards with pre-loaded copay benefit
Typically, available through multiple channels (e.g., rep to HCP to patient; pharmacy to patient; patient via website, Hub live agent, or copay vendor (live agent or IVR); patient and HCP via Hub enrollment form)
Some HCP-administered product programs permit HCPs to enroll on a patient’s behalf through via Hub form

Bridge program

commercial only

Learn More

Overview

Provide patient immediate access to therapy during an insurance delay (typically new starts; some may cover change in insurance)
Limited time/ fill (typically 7-30 days; some may offer additional fill for continued delay up to certain limit)

Patient benefit

100% free (outside of insurance)

Patient eligibility

HCP must enroll patient
May be limited to commercially insured patients (i.e., no government beneficiaries); some programs may allow government beneficiaries

How to sign up

Typically HCP assisted enrollment (via form)

Foundation programs

under insured

no insurance

goverment insurance

65+

Pfizer Oncology Together Form

Pfizer Oncology Together Form - Spanish

Pfizer Patient Assistance Program

Learn More

Overview

Charitable 501(c)(3) organizations provide direct cost-sharing and other support (e.g., travel, counseling) through disease-state funds to indigent patients on first-come first-served basis
These organizations may receive financial contributions from drug manaufacturers for particular disease-state funds that cannot provide funds directly to patients - the foundation must be independent/unaligned

Patient benefit

Patients apply for grants that cover a portion (or all) of their out-of-pocket costs (deductibles and co-pays) until the grant is exhausted

Patient eligibility

Patients must apply and meet eligibility criteria including income level (typically a multiple of federal poverty line), specific diagnosis, insurance status, etc.

How to sign up

Patients submit proof of out-of-pocket drug costs to charities for reimbursement

patient education

Sutent Patient education

Getting started on Sutent

NOT PROVIDED BY BRANDInstructions For Use: Adjuvant Treatment of RCC

NOT PROVIDED BY BRANDInstructions For Use: Advanced RCC

NOT PROVIDED BY BRANDInstructions For Use: Advanced Pancreatic Neuroendocrine Tumors (pNET)

NOT PROVIDED BY BRANDInstructions For Use: Imatinib-resistant or Intolerant GIST